BioAge Labs today disclosed plans for an underwritten public offering of up to $75.0 million of its common stock, with the underwriters granted a 30-day option to purchase an additional $11.25 million of shares. Goldman Sachs & Co. LLC, Piper Sandler and Citigroup will serve as joint book-running managers. The net proceeds, together with existing cash, cash equivalents and marketable securities, are earmarked to advance research, clinical and process development, and manufacturing of lead candidates including BGE-102, to accelerate its NLRP3 and APJ programs, to fund working capital and capital expenditures, to reduce indebtedness, and for other general corporate purposes. The offering is being made under a Form S-3 registration statement effective November 25, 2025, and is subject to market and other customary conditions, with no assurance as to timing, size or terms.

BioAge has initiated an expansion of its BGE-102 NLRP3 inhibitor program into ophthalmology, with a Phase 1b/2a proof-of-concept trial in patients with diabetic macular edema (DME) slated to begin in mid-2026. The randomized, controlled study will evaluate three arms—BGE-102 monotherapy, BGE-102 plus VEGF inhibitor, and control—with the primary endpoint of intraocular IL-6 reduction and exploratory endpoints including best-corrected visual acuity, central subfield thickness and plasma biomarkers. Preclinical data demonstrated dose-dependent preservation of retinal vascular integrity with up to 90% protection from leakage, while ongoing Phase 1 SAD/MAD cohorts have shown robust reductions in hsCRP, IL-6 and IL-1β. Results from the DME trial are anticipated in mid-2027, running in parallel with a Phase 2a cardiovascular risk trial expected to read out in the second half of 2026.